Search results
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | Honolulu Star-Advertiser
Honolulu Star-Advertiser· 5 days agoSHANGHAI >> Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese...
Cheaper Ozempic Alternatives Are Out There. Be Wary of Fakes and Fraudsters.
The Wall Street Journal· 4 days agoMillions of people are taking Ozempic, Wegovy or Mounjaro for weight loss. Compounded drugs are...
Kroger Health revamps weight management program to include GLP-1 drugs
Reuters· 3 days ago, opens new tab that runs pharmacies and clinics across the U.S., said on Friday it had revamped its...
Structure Therapeutics’ stock jumps on weight-loss-pill trial results
Market Watch· 7 days agogained more than 6% premarket on Monday after the company said its experimental weight-loss pill...
Magnificent Seven? Just Two Members Clear This Bar
Investor's Business Daily· 3 days agoAmazon rose 2.05% to 185 on Thursday, reclaiming the 50-day lineand breaking a short downtrend. That offered an early entry in an emerging base. Eli <...
...Nordisk At The Risk Of Stiff Competition In Key Market - Novo Nordisk (NYSE:NVO), Eli Lilly and...
Benzinga· 4 days agoWhat Happened: As reported by Reuters on Sunday, at least 15 Chinese drugmakers are working on...
Alphabet Taps Eli Lilly Executive as New CFO Replacing Porat
Bloomberg via Yahoo Finance· 5 days ago(Bloomberg) -- Alphabet Inc. named Eli Lilly & Co. executive Anat Ashkenazi as its new chief...
Diabetes drug recommended to treat obesity on the NHS
Press Association News via AOL· 6 days agoSubject to final...should be prescribed alongside a reduced-calorie diet and exercise, Nice said. A...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks· 3 days agoEli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
Apple AI Push, Fed, Tesla In Focus; How To Handle This Rally
Investor's Business Daily· 2 days agoAn Eli Lilly Alzheimer's drug and three big earnings loom.